Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. 2011

Eilidh Mowat, and Steve Paterson, and Joanne L Fothergill, and Elli A Wright, and Martin J Ledson, and Martin J Walshaw, and Michael A Brockhurst, and Craig Winstanley
Institute of Infection and Global Health, University of Liverpool, Liverpool L69 3GA, UK.

BACKGROUND Pseudomonas aeruginosa isolates from chronic cystic fibrosis lung infections display multiple phenotypes indicating extensive population diversity. OBJECTIVE We aimed to examine how such diversity is distributed within and between patients, and to study the dynamics of single-strain phenotypic diversity in multiple patients through time. METHODS Sets of 40 P. aeruginosa isolates per sputum samples were analyzed for a series of phenotypic and genotypic characteristics. Population differentiation between patients, between samples within patients, and between isolates within samples was analyzed. RESULTS We characterized 15 traits for a total of 1,720 isolates of an important and widely disseminated epidemic strain of P. aeruginosa from 10 chronically infected patients with cystic fibrosis multiply sampled during 2009. Overall, 43 sputum samples were analyzed and 398 haplotypes of the Liverpool Epidemic Strain were identified. The majority of phenotypic diversity occurred within patients. Such diversity is highly dynamic, displaying rapid turnover of haplotypes through time. P. aeruginosa populations within each individual sputum sample harbored extensive diversity. Although we observed major changes in the haplotype composition within patients between samples taken at intervals of several months, the compositions varied much less during exacerbation periods, despite the use of intravenous antibiotics. Our data also highlight a correlation between periods of pulmonary exacerbation and the overproduction of pyocyanin, a quorum sensing-controlled virulence factor. CONCLUSIONS These results significantly advance our understanding of the within-host population biology of P. aeruginosa during infection of patients with cystic fibrosis, and provide in vivo evidence for a link between pyocyanin production and patient morbidity.

UI MeSH Term Description Entries
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D008297 Male Males
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D011710 Pyocyanine Antibiotic pigment produced by Pseudomonas aeruginosa. Pyocyanin
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D005260 Female Females
D006239 Haplotypes The genetic constitution of individuals with respect to one member of a pair of allelic genes, or sets of genes that are closely linked and tend to be inherited together such as those of the MAJOR HISTOCOMPATIBILITY COMPLEX. Haplotype

Related Publications

Eilidh Mowat, and Steve Paterson, and Joanne L Fothergill, and Elli A Wright, and Martin J Ledson, and Martin J Walshaw, and Michael A Brockhurst, and Craig Winstanley
December 1994, The Journal of infectious diseases,
Eilidh Mowat, and Steve Paterson, and Joanne L Fothergill, and Elli A Wright, and Martin J Ledson, and Martin J Walshaw, and Michael A Brockhurst, and Craig Winstanley
November 2001, International journal of medical microbiology : IJMM,
Eilidh Mowat, and Steve Paterson, and Joanne L Fothergill, and Elli A Wright, and Martin J Ledson, and Martin J Walshaw, and Michael A Brockhurst, and Craig Winstanley
January 2010, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
Eilidh Mowat, and Steve Paterson, and Joanne L Fothergill, and Elli A Wright, and Martin J Ledson, and Martin J Walshaw, and Michael A Brockhurst, and Craig Winstanley
January 2012, PloS one,
Eilidh Mowat, and Steve Paterson, and Joanne L Fothergill, and Elli A Wright, and Martin J Ledson, and Martin J Walshaw, and Michael A Brockhurst, and Craig Winstanley
January 1987, Antibiotics and chemotherapy,
Eilidh Mowat, and Steve Paterson, and Joanne L Fothergill, and Elli A Wright, and Martin J Ledson, and Martin J Walshaw, and Michael A Brockhurst, and Craig Winstanley
April 2015, American journal of respiratory and critical care medicine,
Eilidh Mowat, and Steve Paterson, and Joanne L Fothergill, and Elli A Wright, and Martin J Ledson, and Martin J Walshaw, and Michael A Brockhurst, and Craig Winstanley
September 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Eilidh Mowat, and Steve Paterson, and Joanne L Fothergill, and Elli A Wright, and Martin J Ledson, and Martin J Walshaw, and Michael A Brockhurst, and Craig Winstanley
October 2020, mSphere,
Eilidh Mowat, and Steve Paterson, and Joanne L Fothergill, and Elli A Wright, and Martin J Ledson, and Martin J Walshaw, and Michael A Brockhurst, and Craig Winstanley
May 2016, Trends in microbiology,
Eilidh Mowat, and Steve Paterson, and Joanne L Fothergill, and Elli A Wright, and Martin J Ledson, and Martin J Walshaw, and Michael A Brockhurst, and Craig Winstanley
December 2015, Current opinion in infectious diseases,
Copied contents to your clipboard!